Abstract
Objective To investigate the expressions of phosphatidylinositol 3-kinase (PI3K), Akt and E-cadherin and their clinical significance in thyroid papillary carcinomas. Methods Expressions of PI3K, Akt, and E-cadherin were detected in 62 cases of thyroid papillary carcinomas, 30 cases of thyroid goiter and 30 cases of normal thyroid by immunohistochemistry (EnVison), and simultaneously compared with age, sex, tumor size, clinical tumor node metastasis(TNM) stages, and lymph node metastasis in thyroid papillary carcinomas. Results The expression rate of PI3K, Akt, and E-cadherin was 74.2%(46/62), 66.1%(41/62), 16.1%(10/62), respectively. Expressions of three proteins in thyroid papillary carcinomas were significantly different from those in thyroid goiter and normal thyroid tissues (P<0.05). The lower positive rates of PI3K and Akt proteins were obtained in the group of stage Ⅰ~Ⅱ than that in the group of stage Ⅲ~Ⅳ (χ2=4.976, P=0.026; χ2=6.233, P=0.013). Higher positive rates of PI3K and Akt proteins were obtained in the group of lymph-node metastasis than that in group of non-lymph-node metastasis (χ2=6.675, P=0.010; χ2=7.511, P=0.006). Higher positive rate of E-cadherin protein was obtained in the group of stage Ⅰ~Ⅱ than that in the group of stage Ⅲ~Ⅳ (χ2=6.558, P=0.010). Higher positive rate of E-cadherin proteins was obtained in the group of non-lymph-node metastasis than that in the group of lymph node metastasis(χ2=5.678, P=0.017). There was significant positive correlation between expressions of PI3K and Akt through Spearman correlation analysis (r=0.423, P<0.05). PI3K was negatively correlated with E-cadherin with Spearman correlation analysis (r=-0.527, P<0.05). Akt was also negatively correlated with E-cadherin (r=-0.417, P<0.05). Conclusions PI3K/Akt pathway might regulate thyroid papillary carcinoma cells proliferation, invasion and metastasis. Key words: Thyroid neoplasms/ME; Carcinoma, papillary/ME; 1-phosphatidylinositol 3-kinase/ME; Protein kinases/ME; Cadherins/ME
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
